Multiple Sclerosis Clinical Trial
— EXTREMUSOfficial title:
Home-based EXergames To impRove cognitivE Function in MUltiple Sclerosis: the EXTREMUS Study. A Multicenter, Randomized, Single-blind Non-inferiority Trial
Study design: Phase II, multicenter, randomized, sham-controlled, single-blind, parallel arm, multicenter study to test the hypothesis that home-based exergames is not inferior to home-based cognitive rehabilitation delivered by a software application (app) for mobile devices and both interventions are superior to a placebo-analogue cognitive intervention in improving cognitive function and reducing cognitive-motor interference in people with multiple sclerosis (MS). Procedures: Participants will be randomized in a 1:1:1 ratio to receive an 8-week home-based training with exergames (intervention of interest) or adaptive COGNI-TRAcK (comparator intervention) or sham COGNI-TRAcK (placebo-analogue intervention). Study assessment will be done at study enrolment (baseline), at the end of the 8-week intervention period (immediate post-training, Week 8) and after 16 weeks from randomization (post-training follow-up, Week 16). Investigational interventions: 1. Exergames: home-based repetition of several games delivered by the Nintendo © Wii Balance Board, a commercial off-the-shelf video game console for re-training of balance and postural strategies 2. Adaptive COGNI-TRAcK: adaptive (i.e. automatic adjustment of tasks difficulty) working memory training delivered by a customized application software for mobile devices to self-administer at-home 3. Sham COGNI-TRAcK: non-adaptive (i.e. constant difficulty level) working memory training delivered by the same app as afore described Primary endpoint: changes at the Symbol Digit Modalities Test (SDMT), a measure of sustained attention and information processing speed. Secondary endpoint: changes at the BICAMS (z-scores), a brief, practical and universal assessment tool for cognitive impairment in MS. Additional endpoints: magnitude of cognitive-motor interference estimated as dual-task cost of balance and walking. Sample size estimation: The investigators estimated a pre-defined 8-point non-inferiority margin, based on a significant effect of the COGNI-TRAcK in inducing an about 8-point mean increase at SDMT score (with respect to a sham intervention). Accordingly, 35 participants per arm are required to ensure, with an approximately 85%-power level, that the lower limit of a one-side 95% confidence interval will be above the pre-defined non-inferiority margin. Therefore, considering also a drop-out rate of 25%, a total of 132 subjects should be enrolled.
Status | Recruiting |
Enrollment | 135 |
Est. completion date | September 30, 2022 |
Est. primary completion date | June 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria: - age between 18 and 55 years (inclusive); - cognitive impairment, defined as failure in the SDMT, defined as a corrected score less than 38, i.e. below the 5th percentile of normative value; - Expanded Disability Status Scale (EDSS) score between 2.0 and 5.5; - ability to stand upright for at least 180 seconds without any support; - ability to understand and comply with study requirements; - ability to provide a valid informed consent before any study procedure. Exclusion Criteria: - relapse in the previous 6 months; - initiation of disease-modifying or symptomatic treatments or physiotherapy programme in the 3 months prior to study entry; - any medication/physiotherapy changes occurring over the previous 3 months; - significant visual impairment, defined as a Visual System scoring more than 2 at the Kurtzke Functional Systems Score; - clinically relevant depression, defined as Beck Depression Inventory-II (BDI-II) score equal or more than 14; - overt dementia, defined as an adjusted Mini Mental State Examination (MMSE) score equal or less than 24; - history of epilepsy or seizures; - any medical condition, including musculoskeletal disorders that can interfere with the study conduction. |
Country | Name | City | State |
---|---|---|---|
Italy | Italian MS Foundation | Genova | GE |
Italy | LaRiCE Lab, Don Gnocchi Foundation IRCCS | Milano | MI |
Italy | Dept. of Rehabilitation, M.L. Novarese | Moncrivello | VC |
Italy | A.O. San Camillo, MS Center | Rome | RM |
Lead Sponsor | Collaborator |
---|---|
San Camillo Hospital, Rome | Fondazione Don Carlo Gnocchi Onlus, Fondazione Italiana Sclerosi Multipla, Rehabilitation Unit 'Mons. L. Novarese' Hospital, Moncrivello (VC), IT, University of Chieti |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Cognitive-Motor Interference | Dual-task cost of walking (2-Meter Walking Test) and balance (static posturography) is calculated as percentage change in scores obtained under single-task condition minus dual-task condition divided by the score under single-task condition. Range score: not applicable (negative values are possible). Higher scores mean a better outcome. |
At randomization, 8 weeks and 16 weeks | |
Other | 29-item Multiple Sclerosis Impact Scale | The Multiple Sclerosis Impact Scale (MSIS-29) is a 29-item self-administered questionnaire measuring physical and psychological impact of multiple sclerosis from the patient's perspective. Range score: 0 to 100. Higher scores mean worse outcome. |
At randomization, 8 weeks and 16 weeks | |
Other | 21-item Modified Fatigue Impact Scale | The Modified Fatigue Impact Scale (MFIS) is a 21-item self-administered questionnaire based on items derived from interviews with patients with multiple sclerosis concerning how fatigue impacts their lives; it comprises three subscales (physical, cognitive, and psychosocial functioning). Range score: 0 to 84. Higher scores mean worse outcome. |
At randomization, 8 weeks and 16 weeks | |
Other | Work Productivity and Activity Impairment: Multiple Sclerosis | To quantify absenteeism (missing work because of health problems), presenteeism (impairment while working), overall work impairment, and daily activity impairment attributable to multiple sclerosis. Range score: 0 to 100. Higher scores mean worse outcome. |
At randomization, 8 weeks and 16 weeks | |
Other | Time to first accidental falls | Time to randomization to the first accidental falls reported by the participant, defined as an event which results in a person coming to rest inadvertently on the ground or floor or other lower level (WHO). Range score: not applicable. |
From randomization to study termination (16 weeks) | |
Other | Adverse events | Any untoward medical occurrence in participants which does not necessarily have a causal relationship with the administered intervention. Range score: not applicable. |
From randomization to study termination (16 weeks) | |
Primary | Symbol Digit Modalities Test | The participant is presented with a page headed by a key that pairs the single digits 1-9 with nine symbols. Rows below contain only symbols, the subject's task is to orally report the correct number in the spaces below. After completing the first 10 items with guidance, the subject is timed to determine how many responses can be made in 90 seconds. Range score: not applicable. Higher scores mean a better outcome. Explored domain: Sustained attention and information processing speed. |
Change from randomization to 8-week visit | |
Secondary | Brief International Cognitive Assessment for Multiple Sclerosis | Brief cognitive assessment for multiple sclerosis that includes the Symbol Digit Modalities Test (SDMT) for exploring sustained attention, the initial learning trials of the second edition of the California Verbal Learning Test (CVLT2) for exploring auditory/verbal learning, and the revised Brief Visuospatial Memory Test (BVMTR) for exploring visual/spatial memory. Range score: not applicable. Higher scores mean a better outcome. |
At randomization, 8 weeks and 16 weeks | |
Secondary | Stroop Color-Word Test | The test explores some aspects of executive functions and consists of naming the color of the ink of words, indicating conflicting colors as quickly as possible. Range score: not applicable. Higher scores mean a better outcome. |
At randomization, 8 weeks and 16 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT02845635 -
MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis
|